0001493152-22-007201.txt : 20220317
0001493152-22-007201.hdr.sgml : 20220317
20220317212405
ACCESSION NUMBER: 0001493152-22-007201
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220315
FILED AS OF DATE: 20220317
DATE AS OF CHANGE: 20220317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sundar Padmavathi
CENTRAL INDEX KEY: 0001778709
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 22750871
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
FORMER NAME:
FORMER CONFORMED NAME: Sundar Padma
DATE OF NAME CHANGE: 20190603
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncocyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: 949-409-7600
MAIL ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20200213
FORMER COMPANY:
FORMER CONFORMED NAME: Oncocyte Corp
DATE OF NAME CHANGE: 20200205
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20150513
4
1
ownership.xml
X0306
4
2022-03-15
0
0001642380
Oncocyte Corp
OCX
0001778709
Sundar Padmavathi
15 CUSHING
IRVINE
CA
92618
0
1
0
0
Chief Commercial Officer
Option to Purchase Common Stock
1.150
2022-03-15
4
A
0
87500
0
A
2032-03-15
Common Stock
87500
87500
D
Option to Purchase Common Stock
1.150
2022-03-15
4
A
0
87500
0
A
2032-03-15
Common Stock
87500
87500
D
25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.
/s/ Padmavathi Sundar
2022-03-17